New Mandate Will Help Sell Veriteq's FDA-Approved Microchip (Seeking Alpha article)
Most companies are trying to sell products, but very few companies have the government mandating purchases in their product category. Veriteq (OTCQB:VTEQ) found itself in this enviable position just a few months ago and will continue to enjoy this luck for the near-term future. Because of an FDA ruling with an initial compliance deadline of October 2014, Veriteq will begin to enjoy mandated demand for its niche industry before October 2014 and has forecasted revenue of $239 million - many multiples of its current market capitalization - with 61% gross profit margins. http://seekingalpha.com/article/1939671-new-mandate-will-help-sell-veriteqs-fda-approved-microchip Management Team
Scott R. Silverman, Chairman and CEO
Mr. Silverman has been Chairman and CEO of VeriTeQ since its inception in December 2011. He served as Chairman and CEO of PositiveID Corporation (OTCBB:PSID) from 2008 to August 2011, and Chairman and CEO of VeriChip Corporation (NASDAQ:CHIP) from December 2006 to July 2008. He was Chairman of Digital Angel Corporation from 2003 to 2007. From 2003 to 2006, Silverman served as Chairman and CEO of Applied Digital Solutions (NASDAQ:ADSX). Prior to his role as Chairman and CEO of Applied Digital he held other senior positions with the company. Silverman is an attorney licensed to practice in NJ and PA, and has more than 15 years of executive experience with technology companies. He is a graduate of the University of Pennsylvania and Villanova School of Law.
Randolph K. Geissler, President
Mr. Geissler has been President of VeriTeQ since July 2012 and is also currently the CEO of Geissler Corporation. He specializes in managing companies and technologies focused on RFID, optical imaging and artificial antibodies. His vision and implementation are directly responsible for bringing the implantable microchip from "just an idea" to its highly successful status of more than 80 million microchips implanted in animals worldwide for identification and tracking. He previously served as CEO of Geissler Technologies (2004 - 2008) when he sold the company's expansive product development pipeline. Prior to that, he served as CEO of Digital Angel Corporation (AMEX: DOC) (2000 - 2003) and Destron Fearing (Nasdaq: DFCO) (1993 - 1999), a company he founded. He took his company public (two times) and has broad experience in product development, electronic miniaturization, application of advanced technologies in new markets, and creating marketing alliances; plus extensive experience in establishing strategic intellectual property and patent portfolios.
Caryn Mills, Director of Strategic Alliances
Ms. Mills joined the VeriTeQ team in September 2013, bringing 15-plus years of extensive experience in pharmaceutical and medical device sales, marketing and business development. Prior to joining VeriTeQ, Ms. Mills held top producing sales, management, marketing and business development positions with medical device and pharmaceutical companies including Schering Plough Pharmaceuticals(December 1998-July 2005), King Hospital Surgical Division (July 2005- January 2011), and Covidien Surgical Solutions (January 2011-August 2013). Ms. Mills is responsible for identifying and advancing new partnerships with implantable medical device manufacturers to help them meet federal regulations requiring unique device identification ("UDI"), by using the Company's FDA cleared radio frequency identification microchip "Q inside" within their devices. Ms. Mills will also be responsible for bringing to market the Company's dosimeter technologies for use in radiation therapy treatment.
Allison Tomek, Sr. VP, Investor Relations & Corporate Communications
Ms. Tomek has served as Sr. VP, IR and Corporate Communications of VeriTeQ since its inception and has served as Sr. VP, Investor Relations & Corporate Communications of PositiveID since 2009. She joined PositiveID in January 2007 as VP. From January 2007 to June 2008 she was VP of Investor Relations at Applied Digital Solutions and Digital Angel. From 2003 to 2006, Tomek was Director of Investor Relations and Corporate Communications at Andrx Corporation (NASDAQ:ADRX), a pharmaceutical manufacturer and distributor, and held investor relations positions at RailAmerica (NYSE:RRA) from 2001 to 2003. Tomek is the former President of the National Investor Relations Institute – South Florida chapter and a current member of the chapter’s Board.
Share Structure
Preferred Stock – 5M authorized
411K outstanding
Common Shares – 50M authorized
7M outstanding
http://www.redchip.com/visibility/investor.asp?symbol=VTEQ 